Virtual care is on the rise, with Hims & Hers Health, Inc. and Teladoc Health, Inc. leading the way. HIMS offers a subscription-based telehealth platform for online consultations and prescriptions, while TDOC focuses on virtual medical visits and therapy. Stock performance shows HIMS down 37.4% and TDOC down 9.7% in the past three months.

HIMS and TDOC have different valuations, with HIMS trading at a higher price-to-sales ratio than TDOC. HIMS is focusing on expanding into new health specialties and diagnostics, while TDOC emphasizes enterprise relationships and clinical depth. Analysts predict a 31.9% increase in HIMS stock and a 27.3% increase in TDOC stock.

HIMS is projected to improve its earnings per share by 77.8% in 2025, while TDOC is expected to see a 79.7% improvement in its loss per share. Investors may find HIMS to be a more stable and financially sound investment opportunity at this time, with a stronger push into diagnostics and international expansion. Teladoc Health remains a leading virtual care provider, focusing on enterprise-scale offerings and expanding hospital capabilities.

Read more at Nasdaq: HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling?